Arenicin-1 vs Insulin Degludec
Head-to-head comparison of Arenicin-1 (Arenicin-1) and Insulin Degludec (Insulin degludec (desB30, acylated ultra-long-acting insulin analog)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Arenicin-1 | Insulin Degludec |
|---|---|---|
| Category | Marine-Derived | Diabetes & Metabolic |
| Full Name | Arenicin-1 | Insulin degludec (desB30, acylated ultra-long-acting insulin analog) |
| Molecular Weight | 2079 Da | 6103.9 Da |
| Half-Life | n/a | More than 25 hours |
| Amino Acids | 21 | 50 |
| Typical Dose | n/a | 0.1-0.2 U/kg once daily |
| Route | preclinical | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 76 | 7000 |
| Research Status | Pre-clinical | Approved |
Arenicin-1 Benefits
- ✓antimicrobial
- ✓anti-biofilm
- ✓membrane-active
Insulin Degludec Benefits
- ✓Ultra-long basal coverage
- ✓Lower day-to-day variability
- ✓Reduced nocturnal hypoglycemia
- ✓Flexible dosing time
Arenicin-1 Dosing
bacterial infection|biofilm disruption
Insulin Degludec Dosing
Inject SC once daily|Titrate to fasting glucose and HbA1c response|May be administered with flexible timing in adults
Arenicin-1 Side Effects
- ⚠Arenicola marina
Insulin Degludec Side Effects
- ⚠Hypoglycemia
- ⚠Injection-site reactions
- ⚠Weight gain
Research Overview
Arenicin-1
Marine annelid peptide with strong preclinical antibacterial activity and a stable structural motif that is useful for peptide engineering.
Insulin Degludec
Studies highlight prolonged action and lower glycemic variability compared with many other basal insulins. It is frequently used in research on ultra-long basal coverage and hypoglycemia reduction.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.